Stevanato Group (STVNN) Stock Price & Analysis
STVNN Stock Chart & Stats
- Day’s Range
- MXN 349.52 - MXN 349.52
- 52-Week Range
- MXN 246.00 - MXN 444.62
- Previous Close
- MXN 349.52
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 99.39B
- Enterprise Value
- MXN 5.35B
- Total Cash (Recent Filing)
- MXN 83.58M
- Total Debt (Recent Filing)
- MXN 442.99M
- Price to Earnings (P/E)
- 36.1
- Beta
- 0.04
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 3.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.30%
Bulls Say, Bears Say
Bulls Say
High-value Solutions Growth
Rapid growth in high-value solutions is improving Stevanato’s product mix and deepening its role in biologics and premium injectable therapies. A larger share of specialized offerings can support recurring customer relationships, stronger differentiation, and better long-term earnings quality.
Profitability And Margin Expansion
Strong adjusted EBITDA growth alongside material margin expansion indicates operating leverage and improving profitability in the current business mix. If sustained, higher margins should strengthen internal funding capacity and provide greater resilience as the company scales its specialized platforms.
Conservative Balance Sheet
Moderate leverage and a growing equity base give Stevanato financial capacity to support expansion while limiting balance-sheet strain. This capitalization provides a useful buffer against execution volatility and leaves more flexibility for investment in plants, equipment, and product development.
Bears Say
Weak Free-cash-flow Conversion
Positive operating cash flow is not currently translating into free cash flow because capital spending and working-capital needs are absorbing cash. Persistent volatility or deficits would reduce funding flexibility, increase reliance on financing, and make growth investments harder to self-finance.
Margin And Cost Pressure
The decline from earlier margin peaks suggests that profitability is exposed to cost inflation, investment-related depreciation, and mix or pricing pressure. These factors could limit the durability of recent improvement and constrain earnings growth even when revenue continues expanding.
Engineering Sales-cycle Risk
Longer Engineering sales cycles and project phasing can delay order conversion and make this segment’s revenue less predictable. Although margins improved, continued timing pressure could weaken near-term growth, reduce operating leverage, and complicate execution across the broader portfolio.
Stevanato Group News
STVNN FAQ
What was Stevanato Group’s price range in the past 12 months?
What is Stevanato Group’s market cap?
When is Stevanato Group’s upcoming earnings report date?
How were Stevanato Group’s earnings last quarter?
Is Stevanato Group overvalued?
Does Stevanato Group pay dividends?
What is Stevanato Group’s EPS estimate?
How many shares outstanding does Stevanato Group have?
What happened to Stevanato Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stevanato Group?
What is the TipRanks Smart Score and how is it calculated?
Stevanato Group Stock Smart Score
Company Description
Stevanato Group
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Franco Stevanato
- Employees
- 6,010
- Website
- www.stevanatogroup.com
- Address
- Via Molinella, 17, Piombino Dese, PD, 35017, IT
Stevanato Group (STVNN) Earnings & Revenues
STVNN Company Deck
STVNN Earnings Call
Earnings Call SentimentPositive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.
View all MX:STVNN earnings summariesSTVNN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 6 |
| Technical Analysis | 2 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |








